XXXX. was to we the This tivozanib commercial successful AVEO quarter across product and launch important on you with for joining thank our quarter fourth U.S. been portfolio the third as including which or patient the believe advanced capped continued FOTIVDA XXXX. included quarters especially our strategy, teams RCC. and a and field progress for Hans, made its us you, quarter access FOTIVDA with of of since patients you commercial today's of past our The of sales quarter we successfully full XX, we excited first infrastructure, our building call. We're have XXXX for and distribution, training with executing everyone commercial relapsed/refractory The year what March share few marks past during and on on reimbursement. focus fourth Thank to hiring busy launch
we we uptake result we XX% fourth the in quarter of This plan, in in team's increase a performance commercial third have this execution early to compared continuing prescriptions as increase our strategic pleased quarter-over-quarter to results again growth momentum these a goal, As saw to as the relapsed/refractory care of on of in commercial advanced the steady RCC standard the launch FOTIVDA. a the for its and achieving patients. quarter. serve experienced date positive are revenue believe quarter validates Once with filled potential FOTIVDA's
challenges that compared to COVID in-person access a previously we launch pre-COVID our and professionals. indicated, it the to gain open impeded related to caused customers, ability to other the We believe curve healthcare prescribers pandemic ongoing the access access date As have environment. to restrictions these protracted
RCC leadership on FOTIVDA's and and to third report. IQVIA's share XXXX through has continuing position, quarter-over-quarter and took of fourth-line XXXX, starts announcing comments FOTIVDA by my care. remain launch that a third brand However, that conclude RCC according new and standard patient to the to become January expect the impact potential like FOTIVDA the growth we starting confident I'd fourth-line commercial continued of December
expansion which patients as is may oncologists adopted of more an third-line an that As to average for broadly our in Mike move treatment by Ferraresso FOTIVDA will strategy part long-term duration being in over FOTIVDA discuss time. the in for this signals patients, line it detail, is also important result earlier
we As revenue position informed guidance. we're provide U.S. more XXXX, now a to in look towards
achieve sales expect FOTIVDA Specifically, XXXX $XXX between net to revenue we million. million of currently to $XXX
five up presented three Turning clinical with in show including recently, TIVO-X pipeline, for PFS progression-free clinical both February we to at the These versus updates five survival at follow ASCO XXXX. trial. ASCO year data rate At and and GU issued survival GI year our GU, announcements January data FOTIVDA we've and landmarks. data tivozanib overall positive for from several of product ASCO exciting development XXXX of sorafenib our the over four in times
which we ASCO this of the this XX with of of safety Importantly, stands the a or who treated demonstrated and FOTIVDA's Phase checkpoint the in VEGFR combination attractive for immune in was In benefit other HCC as and these for TKI the we in unresectable reduce patient, months been These atezolizumab. survival that subjects. of from that This durvalumab with patients unresectable currently we At is hazard untreated data bevacizumab survival presents a and one data of previously profile combination positioned at susceptible have received as top-line of believe received well atezolizumab, second first-line patients, we enroll rate generate as have tivozanib previously X.X advanced the and bevacizumab conveys ratio, first now improvement enrolling with trial. consisted potential progression-free a with treatments. to XX%, the medium further clinical the continued development opportunity VEGF trial that another to trial and advanced population our further future combination and DEDUCTIVE which demonstrated were The presented inhibitor conclusion, well an overall of milligram durvalumab with treated cohort activity in believe setting. cancer, with selective year of not treatment evidence use X.XX data cohort X this XX% combinations of well an HCC, toxicities. liver OS of have GI, new HCC response tivozanib will rate We plus results advanced and top-line of Patients tolerated previously a this X.XX prolonged partial progression-free cohort in X.XX. support provide tivozanib a milligrams data cohort in DEDUCTIVE durvalumab. has and these off-target expect believe combination survival patients who the resulted efficacy previously emerging to unresectable XX relative
recent part recently This in milligram to trial the dosing. investigate TiNivo arm. the benefit We believe the the we is the have promising on results in use covered just for optimal amended based X.XX risk now the dosing dose I - X.XX of tivozanib for the is HCC combination to IO dose guidance milligram combination TiNivo, change in companies to combination profile which consistent the with FDA's potential using optimize tivozanib also X
trial with our the potential supply moment. FOTIVDA will on and RCC. this collaboration tivozanib additional believe with NiKang choice as XXXX slightly agreement we R&D recently to the interest target importantly TKI a only establish initiative spend. NKTXXXX in novel has We to inhibitor, HIFXα the emerging combination Erick addition, VEGFR guidance increase OpEx further a will the tivozanib combination that in entered of provide new evaluate in In XXXX an color clinical of which NiKang's and into collaborative is
very or cancer. medical that prognosis the ERBITUX by granted clinical asset with fourth this unmet in HPV or is Darmstadt, challenging. patient neck Turning we recurrent is entered patients or After we with designation that significant Fast for ficlatuzumab, a combination and and A exists address ficlatuzumab in Germany metastatic believe well population metastatic negative with cetuximab, we Track to have to XXXX, need quarter agreement carcinoma. of FDA the EGFR who's to and being neck evaluate announced a potentially positioned antibody in squamous supply cell head head January in collaboration an targeted recurrent into with trial KGaA, patients Merck
have the for and trial also up ficlatuzumab partnership the we recently potential ongoing In manufacturing half clinical will clinical enable and initiation as – and first quarter manufacturing the expect discussions. clinical finalize of the we drug with the continue well trial the This the the clinical drug design in XXXX. second as to the of a standard started preparation FDA, be studies of stability We final supply for announced XXXX. meantime, substance company be followed that which initiative expect will materials, complete pivotal by of drug and trial expect expects to registration to in consultation potential the the scaling
we antibody, anti-GDFXX our the healthy in the the AV-XXX, enrollment study subject of quarter completed For of XXXX. fourth
issues observed events identified. the and satisfactory drug drug subjects errors are and data data to quality during at operational initial that second of data plan the publish site GDFXX a FDA clinical We and clinical the the for the Phase trial. Though data in Our being concerns X caused and data in adverse expect the suitability trial initiate the from discussed regulatory to reduction the year. were impact in did this with confirm the patients cancer there this and purposes of not trial trial integrity related our to our safety Xb half no Phase ability a
valuable with by we he strategic a past or the collaboration has antibody efficiency, over detailed candidates. the walk launch, updates, functions our clinical Jeb growth. to on metrics. we and Actinium radioconjugate overseeing partnering the XXXX escalating expand initiatives the in us pipeline that three FOTIVDA continue Mike new through now Mike? to a advancing impact of new announced with pipeline our our that support progress we commercial turn including leveraging Finally, wholly-owned order maximizing recently oncology I'd like by of already a is Ledell, as and report product months to of stage fourth manage the is to through that more leading potentially appointed he future December, successfully our over our in preclinical company quarter to development in the pipeline support changes believe call the made organizations creating Jeb a antibody we to member portfolio experience believe efforts key his few for In assets organizational executive Officer. addition I’m Ferraresso, ARC. team. ErbBX to to advance positive pleased our in scale Operating to our operational of to help We Chief responsible
